Polymorph 2 Pain Relief Compound Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuropathic pain and other types of pain have low to moderate efficacy, leaving many patients without significant pain relief, and existing medications often come with undesirable side effects.
Innovation Solution
A polymorphic form of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide, referred to as polymorph 2, which is less hygroscopic, more stable, and more bioavailable than other crystal forms, is used to treat or prevent pain, inflammation, and autoimmunity, offering improved pharmacokinetic properties and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used for pain relief, then pain management is provided, but efficacy is low to moderate and side effects occur
Solution Approach 1:
The patent applies parameter changes by transitioning from racemic mixtures to pure (S,S)-enantiomer forms of the compound. This stereochemical parameter change results in enhanced analgesic efficacy and reduced side effects, as the pure enantiomer provides more selective and potent interaction with pain receptors while minimizing off-target effects that cause adverse reactions.
Solution Approach 2:
The patent utilizes phase transitions by discovering and characterizing different polymorphic forms (Form 1 and Form 2) of the (S,S)-enantiomer. Form 2 represents a more stable polymorphic phase that provides improved bioavailability, faster dissolution rates, and more consistent pharmacokinetic profiles compared to Form 1, thereby enhancing therapeutic reliability while maintaining safety.
2Reliability
If polymorph 2 is used, then bioavailability and stability are enhanced, but manufacturing complexity increases due to polymorph control requirements
Solution Approach 1:
The patent applies preliminary action by establishing specific crystallization conditions and processing parameters during manufacturing that pre-determine the formation of Form 2. By controlling nucleation and crystal growth conditions in advance (temperature profiles, solvent selection, addition rates), the process ensures consistent formation of the desired polymorph, eliminating the need for complex post-manufacturing polymorph conversion or separation steps.
Solution Approach 2:
The patent uses intermediary substances or conditions (specific solvents, additives, or crystallization agents) that mediate the formation of Form 2 during the manufacturing process. These intermediaries facilitate selective nucleation and growth of the desired polymorphic form, simplifying the overall manufacturing complexity while ensuring high bioavailability and stability of the final product.
Data Source
AI summary
The present invention relates to a polymorphic form of (S,S)-2-N(3-O-(propan-2-ol)-1-propyl-4-hydroxybenzene)-3-phenylpropylamide or synonymously named N-[2-(4-Hydroxy-phenyl)-(2-hydroxy-propoxymethyl)-ethyl]-3-phenyl-propionamide and to the treatment or prophylaxis of pain, inflammation and/or autoimmunity and provides a method of treating or preventing pain, inflammation and/or autoimmunity as well as the use of this polymorphic form in the manufacture of medicaments for the treatment or prophylaxis of pain (preferably nociceptive or neuropathic), inflammation and/or autoimmunity in humans and/or non-human animals.